| Year |
Citation |
Score |
| 2023 |
Sun MA, Yang R, Liu H, Wang W, Song X, Hu B, Reynolds N, Roso K, Chen LH, Greer PK, Keir ST, McLendon RE, Cheng SY, Bigner DD, Ashley DM, et al. Repurposing Clemastine to Target Glioblastoma Cell Stemness. Cancers. 15. PMID 37760589 DOI: 10.3390/cancers15184619 |
0.428 |
|
| 2023 |
Thompson EM, Landi D, Brown MC, Friedman HS, McLendon R, Herndon JE, Buckley E, Bolognesi DP, Lipp E, Schroeder K, Becher OJ, Friedman AH, McKay Z, Walter A, Threatt S, et al. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial. The Lancet. Child & Adolescent Health. PMID 37004712 DOI: 10.1016/S2352-4642(23)00031-7 |
0.451 |
|
| 2023 |
Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, et al. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science Translational Medicine. 15: eabn5649. PMID 36753564 DOI: 10.1126/scitranslmed.abn5649 |
0.443 |
|
| 2021 |
Gromeier M, Brown MC, Zhang G, Lin X, Chen Y, Wei Z, Beaubier N, Yan H, He Y, Desjardins A, Herndon JE, Varn FS, Verhaak RG, Zhao J, Bolognesi DP, ... ... McLendon RE, et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nature Communications. 12: 352. PMID 33441554 DOI: 10.1038/s41467-020-20469-6 |
0.511 |
|
| 2020 |
Chen LH, Pan C, Diplas BH, Xu C, Hansen LJ, Wu Y, Chen X, Geng Y, Sun T, Sun Y, Zhang P, Wu Z, Zhang J, Li D, Zhang Y, ... ... McLendon RE, et al. The integrated genomic and epigenomic landscape of brainstem glioma. Nature Communications. 11: 3077. PMID 32555164 DOI: 10.1038/S41467-020-16682-Y |
0.373 |
|
| 2019 |
Batich KA, Riedel RF, Kirkpatrick JP, Tong BC, Eward WC, Tan CL, Pittman PD, McLendon RE, Peters KB. Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. Frontiers in Oncology. 9: 1322. PMID 31850213 DOI: 10.3389/Fonc.2019.01322 |
0.342 |
|
| 2019 |
Flores C, Wildes T, Dean BD, Moore G, Drake J, Abraham R, Gil J, Yegorov O, Yang C, Dean J, Moneypenny C, Shin D, Pham C, Krauser J, King J, ... ... McLendon R, et al. Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Science Advances. 5: eaav9879. PMID 31807694 DOI: 10.1126/Sciadv.Aav9879 |
0.393 |
|
| 2019 |
Thomas C, Wefers A, Bens S, Nemes K, Agaimy A, Oyen F, Vogelgesang S, Rodriguez FJ, Brett FM, McLendon R, Bodi I, Burel-Vandenbos F, Keyvani K, Tippelt S, Poulsen FR, et al. Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathologica. PMID 31732806 DOI: 10.1007/S00401-019-02094-W |
0.442 |
|
| 2019 |
Harrison W, Elsamadicy AA, McMahon JT, Chagoya G, Sobel RA, McLendon RE, Adamson C. Glioneuronal Tumor With Features of Ganglioglioma and Neurocytoma Arising in the Fourth Ventricle: A Report of 2 Unusual Cases and a Review of Infratentorial Gangliogliomas. Journal of Neuropathology and Experimental Neurology. PMID 31361005 DOI: 10.1093/Jnen/Nlz060 |
0.388 |
|
| 2019 |
Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, ... ... McLendon RE, et al. MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation. Cancer Research. PMID 31040154 DOI: 10.1158/0008-5472.Can-18-1010 |
0.476 |
|
| 2019 |
Harrison WT, Bouldin T, Buckley A, Estrada J, McLendon R, Janssen K. Sudden Unexpected Death in a Child From an Anaplastic Ependymoma. The American Journal of Forensic Medicine and Pathology. PMID 30958386 DOI: 10.1097/Paf.0000000000000480 |
0.341 |
|
| 2019 |
Lehman NL, Usubalieva A, Lin T, Allen SJ, Tran QT, Mobley BC, McLendon RE, Schniederjan MJ, Georgescu MM, Couce M, Dulai MS, Raisanen JM, Al Abbadi M, Palmer CA, Hattab EM, et al. Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. Acta Neuropathologica Communications. 7: 42. PMID 30876455 DOI: 10.1186/S40478-019-0689-3 |
0.421 |
|
| 2019 |
Hoeman CM, Cordero FJ, Hu G, Misuraca K, Romero MM, Cardona HJ, Nazarian J, Hashizume R, McLendon R, Yu P, Procissi D, Gadd S, Becher OJ. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nature Communications. 10: 1023. PMID 30833574 DOI: 10.1038/S41467-019-08823-9 |
0.373 |
|
| 2019 |
Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE. MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology. 78: 57-64. PMID 30500933 DOI: 10.1093/Jnen/Nly110 |
0.498 |
|
| 2019 |
Gromeier M, Brown M, Beuabier N, Yan H, He Y, Zhang G, Desjardins A, Herndon J, Bolognesi D, Friedman A, Friedman H, McSherry F, Lin X, Wei Z, Nair S, ... ... McLendon R, et al. ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES Neuro-Oncology. 21: vi7-vi7. DOI: 10.1093/Neuonc/Noz175.026 |
0.56 |
|
| 2018 |
Ahn JS, Harrison W, Hughes E, McLendon RE. Intraventricular Pilocytic Astrocytoma With KIAA1549/BRAF Fusion Arising in a 44-Year Old. Journal of Neuropathology and Experimental Neurology. PMID 30561708 DOI: 10.1093/Jnen/Nly116 |
0.322 |
|
| 2018 |
Tan CL, Pang YH, Lim KHC, Sein L, Codd PJ, McLendon RE. Two Extraordinary Sellar Neuronal Tumors: Literature Review and Comparison of Clinicopathologic Features. American Journal of Clinical Pathology. PMID 30551183 DOI: 10.1093/Ajcp/Aqy155 |
0.355 |
|
| 2018 |
Lipp ES, McLendon RE. Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. Seminars in Oncology Nursing. PMID 30409555 DOI: 10.1016/J.Soncn.2018.10.002 |
0.327 |
|
| 2018 |
Diplas BH, Liu H, Yang R, Hansen LJ, Zachem AL, Zhao F, Bigner DD, McLendon RE, Jiao Y, He Y, Waitkus MS, Yan H. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas. Neuro-Oncology. PMID 30346624 DOI: 10.1093/Neuonc/Noy167 |
0.445 |
|
| 2018 |
Tan CL, Vellayappan B, Wu B, Yeo TT, McLendon RE. Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism. Brain Tumor Pathology. PMID 30159860 DOI: 10.1007/S10014-018-0327-Y |
0.392 |
|
| 2018 |
Thompson EM, Halvorson K, McLendon R. Sulfonylurea receptor 1 expression is variable in adult and pediatric brain tumors. Clinical Neuropathology. PMID 30079884 DOI: 10.5414/Np301102 |
0.368 |
|
| 2018 |
Tan CL, Kimpo MS, Nga VDW, Poon KS, McLendon RE. Intracerebral Flexner-Wintersteiner Rosette-Rich Tumor With Somatic RB1 Mutation: A CNS Embryonal Tumor With Retinoblastic Differentiation. Journal of Neuropathology and Experimental Neurology. PMID 30053065 DOI: 10.1093/Jnen/Nly062 |
0.425 |
|
| 2018 |
Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, Congdon KL, Sanchez-Perez L, McLendon RE, Archer GE, Fecci P, Sampson JH. Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. PMID 30041899 DOI: 10.1016/J.Jocn.2018.06.005 |
0.305 |
|
| 2018 |
Tan CL, Landi D, Fuchs H, McLendon RE. Novel case of recurrent intraventricular atypical central neurocytoma with prominent gangliogliomatous differentiation in a 10-year-old boy with 10 years of follow up. Neuropathology : Official Journal of the Japanese Society of Neuropathology. PMID 30039530 DOI: 10.1111/Neup.12502 |
0.363 |
|
| 2018 |
Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, ... McLendon RE, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica. PMID 30019219 DOI: 10.1007/S00401-018-1888-X |
0.381 |
|
| 2018 |
Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, ... McLendon RE, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine. PMID 29943666 DOI: 10.1056/Nejmoa1716435 |
0.544 |
|
| 2018 |
Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M. Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology. PMID 29878245 DOI: 10.1093/Jnen/Nly045 |
0.524 |
|
| 2018 |
Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, ... ... McLendon RE, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications. 9: 2087. PMID 29802247 DOI: 10.1038/S41467-018-04448-6 |
0.482 |
|
| 2018 |
Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy P, Herndon JE, McLendon RE, Keir ST, Archer GE, et al. A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29703821 DOI: 10.1158/1078-0432.Ccr-17-0126 |
0.543 |
|
| 2018 |
Thompson E, Brown M, Dobrikova E, Ramaswamy V, Taylor M, McLendon R, Chandramohan V, Bigner D, Gromeier M. PDTM-46. POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA Neuro-Oncology. 20: vi213-vi213. DOI: 10.1093/Neuonc/Noy148.885 |
0.495 |
|
| 2018 |
Diplas B, Waitkus M, He X, Brosnan-Cashman J, Liu H, Chen L, Wang Z, Moure C, Killela P, Lipp E, Rodriguez F, Jiao Y, McLendon R, Bigner D, Meeker A, et al. GENE-42. THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA Neuro-Oncology. 20: vi112-vi112. DOI: 10.1093/Neuonc/Noy148.468 |
0.41 |
|
| 2018 |
Landi D, Thompson E, McLendon R, Desjardins A, Chandramohan V, Ashley D, Bigner D. IMMU-21. TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN Neuro-Oncology. 20: i103-i103. DOI: 10.1093/Neuonc/Noy059.337 |
0.506 |
|
| 2017 |
Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojeic I, McLendon RE, Friedman HS, He Y, et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H) induced metabolic liabilities. Cancer Research. PMID 29097607 DOI: 10.1158/0008-5472.Can-17-1352 |
0.505 |
|
| 2017 |
Reap E, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, ... ... Mclendon R, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells which target cytomegalovirus in glioblastoma. Cancer Research. PMID 29093005 DOI: 10.1158/0008-5472.Can-17-0469 |
0.484 |
|
| 2017 |
Yang R, Chen LH, Hansen LJ, Carpenter AB, Moure CJ, Liu H, Pirozzi CJ, Diplas BH, Waitkus MS, Greer PK, Zhu H, McLendon RE, Bigner DD, He Y, Yan H. Cic loss promotes gliomagenesis via aberrant neural stem cell proliferation and differentiation. Cancer Research. PMID 28939681 DOI: 10.1158/0008-5472.Can-17-1018 |
0.492 |
|
| 2017 |
Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Archives of Pathology & Laboratory Medicine. PMID 28829151 DOI: 10.5858/Arpa.2016-0580-Oa |
0.516 |
|
| 2017 |
Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, Gröbner S, Segura-Wang M, Zichner T, Rudneva VA, Warnatz HJ, Sidiropoulos N, Phillips AH, Schumacher S, Kleinheinz K, ... ... McLendon RE, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 547: 311-317. PMID 28726821 DOI: 10.1038/Nature22973 |
0.333 |
|
| 2017 |
Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE, Murphy SK, Hashizume R, Becher OJ. Histone H3.3K27M represses p16 to accelerate gliomagenesis in a murine model of DIPG. Molecular Cancer Research : McR. PMID 28522693 DOI: 10.1158/1541-7786.Mcr-16-0389 |
0.358 |
|
| 2017 |
Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 1898-1909. PMID 28411277 DOI: 10.1158/1078-0432.Ccr-16-2057 |
0.519 |
|
| 2017 |
Bruner JM, Louis DN, McLendon R, Rosenblum MK, Archambault WT, Most S, Tihan T. The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. Journal of Neuropathology and Experimental Neurology. 76: 189-194. PMID 28395084 DOI: 10.1093/Jnen/Nlw122 |
0.343 |
|
| 2017 |
Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, et al. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Molecular Cancer Research : McR. PMID 28148827 DOI: 10.1158/1541-7786.Mcr-16-0485 |
0.55 |
|
| 2016 |
Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, Chen C, Xie Q, Mack SC, Wang X, Carcaboso AM, Sloan AE, Ouyang G, McLendon RE, Bian XW, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. The Journal of Experimental Medicine. PMID 27923907 DOI: 10.1084/Jem.20151673 |
0.34 |
|
| 2016 |
Lehman NL, Hattab EM, Mobley BC, Usubalieva A, Schniederjan MJ, McLendon RE, Paulus W, Rushing EJ, Georgescu MM, Couce M, Dulai MS, Cohen ML, Pierson CR, Raisanen JM, Martin SE, et al. Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults. Neuro-Oncology. PMID 27416954 DOI: 10.1093/Neuonc/Now118 |
0.342 |
|
| 2016 |
Strowd RE, Rodriguez FJ, McLendon RE, Vredenburgh JJ, Chance AB, Jallo G, Olivi A, Ahn ES, Blakeley JO. Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. American Journal of Medical Genetics. Part A. PMID 26992069 DOI: 10.1002/Ajmg.A.37622 |
0.313 |
|
| 2016 |
Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet. Oncology. PMID 26976201 DOI: 10.1016/S1470-2045(15)00581-1 |
0.456 |
|
| 2016 |
Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE, Rich JN. A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Research. PMID 26896279 DOI: 10.1158/0008-5472.Can-15-2402 |
0.404 |
|
| 2016 |
Hu J, Sun T, Wang H, Chen Z, Wang S, Yuan L, Liu T, Li HR, Wang P, Feng Y, Wang Q, McLendon RE, Friedman AH, Keir ST, Bigner DD, et al. MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell. 29: 49-60. PMID 26766590 DOI: 10.1016/J.Ccell.2015.12.005 |
0.432 |
|
| 2016 |
Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Investigational New Drugs. PMID 26728879 DOI: 10.1007/S10637-015-0318-3 |
0.451 |
|
| 2015 |
Pham CD, Flores C, Yang C, Pinheiro EM, Yearley JH, Sayour E, Pei Y, Moore C, McLendon RE, Huang J, Sampson JH, Wechsler-Reya RJ, Mitchell DA. Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26405194 DOI: 10.1158/1078-0432.Ccr-15-0713 |
0.337 |
|
| 2015 |
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, ... ... Mclendon R, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/Nejmoa1402121 |
0.478 |
|
| 2015 |
Gururangan S, Robinson G, Ellison DW, Wu G, He X, Lu QR, McLendon R, Grant G, Driscoll T, Neuberg R. Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood & Cancer. 62: 1855-8. PMID 25940061 DOI: 10.1002/Pbc.25560 |
0.445 |
|
| 2015 |
Lopez G, McLendon RE, Peters KB. Supratentorial tanycytic ependymoma in an adult male: case report and review of literature. Case Reports in Oncology. 8: 159-63. PMID 25873884 DOI: 10.1159/000380906 |
0.307 |
|
| 2015 |
Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 519: 366-9. PMID 25762141 DOI: 10.1038/Nature14320 |
0.477 |
|
| 2015 |
Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, Mclendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. Journal of Neurochemistry. 133: 730-8. PMID 25598002 DOI: 10.1111/Jnc.13032 |
0.508 |
|
| 2015 |
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, Rich JN, Bao S. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nature Cell Biology. 17: 170-82. PMID 25580734 DOI: 10.1038/Ncb3090 |
0.403 |
|
| 2015 |
Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, Sampson JH, Mitchell DA. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunology, Immunotherapy : Cii. 64: 419-27. PMID 25555571 DOI: 10.1007/S00262-014-1651-7 |
0.34 |
|
| 2015 |
Pham C, Flores C, Yang C, Sayour E, Pei Y, Moore C, McLendon R, Huang J, Sampson J, Wechsler-Reya R, Mitchell D. IMPS-25DIFFERENTIAL TUMOR MICROENVIRONMENTS AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN MOLECULAR SUBTYPES OF MURINE MEDULLOBLASTOMA Neuro-Oncology. 17: v118.3-v118. DOI: 10.1093/Neuonc/Nov217.24 |
0.403 |
|
| 2014 |
Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST, Bigner DD, Li QJ, Wang H, Wang XF. miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. The Journal of Clinical Investigation. 124: 4489-502. PMID 25202981 DOI: 10.1172/Jci75284 |
0.446 |
|
| 2014 |
Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, ... ... McLendon RE, et al. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. The Journal of Clinical Investigation. 124: 3741-56. PMID 25061874 DOI: 10.1172/Jci73093 |
0.444 |
|
| 2014 |
Zhang L, Chen LH, Wan H, Yang R, Wang Z, Feng J, Yang S, Jones S, Wang S, Zhou W, Zhu H, Killela PJ, Zhang J, Wu Z, Li G, ... ... McLendon RE, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nature Genetics. 46: 726-30. PMID 24880341 DOI: 10.1038/Ng.2995 |
0.521 |
|
| 2014 |
Babu R, Kranz PG, Agarwal V, McLendon RE, Thomas S, Friedman AH, Bigner DD, Adamson C. Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. Journal of Neuro-Oncology. 119: 177-85. PMID 24838419 DOI: 10.1007/S11060-014-1471-9 |
0.563 |
|
| 2014 |
Fang X, Huang Z, Zhou W, Wu Q, Sloan AE, Ouyang G, McLendon RE, Yu JS, Rich JN, Bao S. The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (Dayton, Ohio). 32: 2033-47. PMID 24831540 DOI: 10.1002/Stem.1730 |
0.337 |
|
| 2014 |
Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. Plos One. 9: e94281. PMID 24722266 DOI: 10.1371/Journal.Pone.0094281 |
0.564 |
|
| 2014 |
Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, ... ... McLendon RE, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 5: 1515-25. PMID 24722048 DOI: 10.18632/Oncotarget.1765 |
0.521 |
|
| 2014 |
Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, ... ... McLendon RE, et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Reports. 6: 117-29. PMID 24373972 DOI: 10.1016/J.Celrep.2013.11.043 |
0.305 |
|
| 2014 |
Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro-Oncology. 16: 310-7. PMID 24311632 DOI: 10.1093/Neuonc/Not154 |
0.397 |
|
| 2014 |
Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 5: 1452-7. PMID 24140581 DOI: 10.18632/Oncotarget.1505 |
0.499 |
|
| 2014 |
López GY, Grant GA, Fuchs HE, Leithe LG, Gururangan S, Bigner DD, Yan H, McLendon RE, He Y. Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations. Neuropathology and Applied Neurobiology. 40: 217-20. PMID 23659599 DOI: 10.1111/Nan.12060 |
0.525 |
|
| 2014 |
Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, Leon GD, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH. D-270MG FLuc/GFP xenograft is highly invasive in NSG mice. Plos One. DOI: 10.1371/Journal.Pone.0094281.G001 |
0.408 |
|
| 2014 |
Guo C, Chen LH, Huang Y, Chang C, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. Abstract LB-82: MLL2 maintains neoplastic cell growth and global histone H3 lysine 4 monomethylation Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-82 |
0.451 |
|
| 2014 |
Pirozzi CJ, Wang CY, Carpenter AB, Zhu H, Greer PK, McLendon RE, Bigner DD, He Y, Yan H. Abstract 63: Driving brain tumorigenesis: Generation of a mutant IDH1 mouse model of progressive glioma Cancer Research. 74: 63-63. DOI: 10.1158/1538-7445.Am2014-63 |
0.542 |
|
| 2014 |
Mowery Y, Wright A, Desjardins A, Peters K, Ranjan T, Vlahovic G, Friedman H, Zomorodi A, Kaylie D, Adogwa O, Nimjee S, Sperduto W, Chagoya G, Fatemi P, McLendon R, et al. MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS Neuro-Oncology. 16: v130-v131. DOI: 10.1093/Neuonc/Nou260.18 |
0.36 |
|
| 2014 |
McLendon RE, Lipp E, Gururangan S, Fuchs H, Zagzag D, Herndon J, Healy P. PROGNOSTIC MARKER ANALYSIS IN PEDIATRIC POSTERIOR FOSSA EPENDYMOMAS Neuro-Oncology. 16: iii27-iii27. DOI: 10.1093/Neuonc/Nou208.17 |
0.318 |
|
| 2013 |
Guo C, Chen LH, Huang Y, Chang CC, Wang P, Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, Yan H, Keir ST, Bigner DD, He Y. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 4: 2144-53. PMID 24240169 DOI: 10.18632/Oncotarget.1555 |
0.476 |
|
| 2013 |
Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, ... ... McLendon RE, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica. 126: 917-29. PMID 24174164 DOI: 10.1007/S00401-013-1198-2 |
0.502 |
|
| 2013 |
Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schüller U, Gururangan S, McLendon R, Bigner D, Fouladi M, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet. Oncology. 14: 1200-7. PMID 24140199 DOI: 10.1016/S1470-2045(13)70449-2 |
0.481 |
|
| 2013 |
Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 119: 4180-7. PMID 24104527 DOI: 10.1002/Cncr.28343 |
0.398 |
|
| 2013 |
Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, ... ... McLendon RE, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nature Genetics. 45: 1141-9. PMID 23917401 DOI: 10.1038/Ng.2734 |
0.484 |
|
| 2013 |
Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, Aldape KD, McLendon RE, Lehman NL, Miller CR, Schniederjan MJ, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4951-60. PMID 23864165 DOI: 10.1158/1078-0432.Ccr-13-0551 |
0.392 |
|
| 2013 |
Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4717-27. PMID 23857604 DOI: 10.1158/1078-0432.Ccr-12-3891 |
0.505 |
|
| 2013 |
Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE, McLendon RE, Friedman HS. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Journal of Neuro-Oncology. 114: 135-40. PMID 23686298 DOI: 10.1007/S11060-013-1162-Y |
0.342 |
|
| 2013 |
Babu R, Hatef J, McLendon RE, Cummings TJ, Sampson JH, Friedman AH, Adamson C. Clinicopathological characteristics and treatment of rhabdoid glioblastoma. Journal of Neurosurgery. 119: 412-9. PMID 23641829 DOI: 10.3171/2013.3.Jns121773 |
0.424 |
|
| 2013 |
Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, Salmasi V, Riggins GJ, Reitman ZJ, Rasheed A, Keir S, ... ... McLendon R, et al. Exomic sequencing of four rare central nervous system tumor types. Oncotarget. 4: 572-83. PMID 23592488 DOI: 10.18632/Oncotarget.964 |
0.535 |
|
| 2013 |
Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN, Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 153: 139-52. PMID 23540695 DOI: 10.1016/J.Cell.2013.02.021 |
0.375 |
|
| 2013 |
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, ... ... McLendon RE, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18 |
0.56 |
|
| 2013 |
Zhang J, Babu R, McLendon RE, Friedman AH, Adamson C. A comprehensive analysis of 41 patients with rosette-forming glioneuronal tumors of the fourth ventricle. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 20: 335-41. PMID 23375398 DOI: 10.1016/J.Jocn.2012.09.003 |
0.42 |
|
| 2013 |
Curtis VF, Wang H, Yang P, McLendon RE, Li X, Zhou QY, Wang XF. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. Plos One. 8: e54916. PMID 23372791 DOI: 10.1371/Journal.Pone.0054916 |
0.395 |
|
| 2013 |
Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 900-8. PMID 23363814 DOI: 10.1158/1078-0432.Ccr-12-1707 |
0.369 |
|
| 2013 |
Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, Yan H. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Research. 73: 496-501. PMID 23204232 DOI: 10.1158/0008-5472.Can-12-2852 |
0.474 |
|
| 2013 |
Bao X, Chandramohan V, Keir ST, Pegram CN, McLendon RE, Kuan C, Pastan IH, Bigner DD. Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P126 |
0.483 |
|
| 2013 |
Ramaswamy V, Remke M, Bouffet E, Shih D, Faria C, Schüller U, Gururangan S, McLendon R, Jabado N, Fontebasso A, Dunn S, Triscott J, Hawkins C, Tabori U, Codispoti K, et al. Abstract 3552: Subgroup-specific pattern of recurrence in medulloblastoma. Cancer Research. 73: 3552-3552. DOI: 10.1158/1538-7445.Am2013-3552 |
0.408 |
|
| 2012 |
Kernagis D, Datto M, McLendon R, Grant GA. 164 L1CAM as a Marker of an Aggressive Tumor Phenotype in Children with Juvenile Pilocytic Astrocytoma. Neurosurgery. 71: E565. PMID 28175762 DOI: 10.1227/01.Neu.0000417754.93159.A8 |
0.338 |
|
| 2012 |
Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, et al. Laminin alpha 2 enables glioblastoma stem cell growth. Annals of Neurology. 72: 766-78. PMID 23280793 DOI: 10.1002/Ana.23674 |
0.414 |
|
| 2012 |
Guo C, Chang CC, Wortham M, Chen LH, Kernagis DN, Qin X, Cho YW, Chi JT, Grant GA, McLendon RE, Yan H, Ge K, Papadopoulos N, Bigner DD, He Y. Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proceedings of the National Academy of Sciences of the United States of America. 109: 17603-8. PMID 23045699 DOI: 10.1073/Pnas.1208807109 |
0.445 |
|
| 2012 |
Duong LM, McCarthy BJ, McLendon RE, Dolecek TA, Kruchko C, Douglas LL, Ajani UA. Descriptive epidemiology of malignant and nonmalignant primary spinal cord, spinal meninges, and cauda equina tumors, United States, 2004-2007. Cancer. 118: 4220-7. PMID 22907705 DOI: 10.1002/Cncr.27390 |
0.318 |
|
| 2012 |
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, ... ... McLendon R, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3: 709-22. PMID 22869205 DOI: 10.18632/Oncotarget.588 |
0.639 |
|
| 2012 |
Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, ... ... McLendon RE, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 488: 49-56. PMID 22832581 DOI: 10.1038/Nature11327 |
0.476 |
|
| 2012 |
Blaney SM, Kocak M, Gajjar A, Chintagumpala M, Merchant T, Kieran M, Pollack IF, Gururangan S, Geyer R, Phillips P, McLendon RE, Packer R, Goldman S, Banerjee A, Heideman R, et al. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). Journal of Neuro-Oncology. 109: 565-71. PMID 22790443 DOI: 10.1007/S11060-012-0929-X |
0.402 |
|
| 2012 |
Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS, Reardon DA. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neuro-Oncology. 109: 63-70. PMID 22535433 DOI: 10.1007/S11060-012-0861-0 |
0.404 |
|
| 2012 |
Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology. 108: 499-506. PMID 22407177 DOI: 10.1007/S11060-012-0848-X |
0.351 |
|
| 2012 |
Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. Plos One. 7: e31046. PMID 22383993 DOI: 10.1371/Journal.Pone.0031046 |
0.461 |
|
| 2012 |
Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 118: 4759-67. PMID 22371319 DOI: 10.1002/Cncr.26541 |
0.337 |
|
| 2012 |
Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 21: 155-67. PMID 22340590 DOI: 10.1016/J.Ccr.2011.12.021 |
0.425 |
|
| 2012 |
Lin N, Di C, Bortoff K, Fu J, Truszkowski P, Killela P, Duncan C, McLendon R, Bigner D, Gregory S, Adamson DC. Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. Molecular Cancer Research : McR. 10: 208-17. PMID 22241217 DOI: 10.1158/1541-7786.Mcr-10-0109 |
0.549 |
|
| 2012 |
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology. 107: 155-64. PMID 21986722 DOI: 10.1007/S11060-011-0722-2 |
0.374 |
|
| 2012 |
Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. Journal of Neuro-Oncology. 106: 643-9. PMID 21968943 DOI: 10.1007/S11060-011-0709-Z |
0.371 |
|
| 2012 |
Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nuclear Medicine and Biology. 39: 23-34. PMID 21958852 DOI: 10.1016/J.Nucmedbio.2011.06.005 |
0.525 |
|
| 2012 |
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology. 106: 409-15. PMID 21938530 DOI: 10.1007/S11060-011-0687-1 |
0.415 |
|
| 2012 |
Chin BB, Hjelemand A, Rich J, Song H, Lascola C, Storms R, McLendon R, Reiman R, Greer KL, Metzler SD, McDougald D, Dai D, Vaidyanathan G. Synthesis and preliminary evaluation of n.c.a. iodoquine: a novel radiotracer with high uptake in cells with high ALDH1 expression. Current Radiopharmaceuticals. 5: 47-58. PMID 21864242 DOI: 10.2174/1874471011205010047 |
0.318 |
|
| 2012 |
Kulig K, McLendon RE, Locke SC, Young DR, Zhong X, Hudson LL, Abernethy AP. MET and ALK in glioblastoma multiforme (GBM): Comparison of IHC and FISH. Journal of Clinical Oncology. 30: 2021-2021. DOI: 10.1200/Jco.2012.30.15_Suppl.2021 |
0.384 |
|
| 2012 |
Antoun GR, McLendon R, Friedman H, Friedman A, Bigner D, Ali-Osman F. Abstract 1177: The mutational status of the p53 tumor suppressor gene is a determinant of GSTP1 expression and mediates GSTP1-dependent drug resistance in human glioblastoma Cancer Research. 72: 1177-1177. DOI: 10.1158/1538-7445.Am2012-1177 |
0.376 |
|
| 2012 |
Coleman B, McLendon R, Kranz PG, Adamson DC. Medulloblastoma Contemporary Neurosurgery. 34: 1-5. DOI: 10.1097/01.Cne.0000412525.73097.3E |
0.3 |
|
| 2012 |
Pollack IF, Jakacki RI, Butterfield L, Okada H, Chiba Y, Hashimoto N, Kagawa N, Kinoshita M, Kijima N, Hirayama R, Oji Y, Tsuboi A, Oka Y, Sugiyama H, Yoshimine T, ... ... McLendon R, et al. CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES Neuro-Oncology. 14: vi43-vi49. DOI: 10.1093/Neuonc/Nos224 |
0.409 |
|
| 2012 |
Fujita M, Zhang R, Nakata S, Kuzushima K, Wainwright DA, Balyasnikova IV, Auffinger B, Ahmed AU, Han Y, Lesniak MS, Knight A, Arnouk H, Gillespie GY, Britt W, Su Y, ... ... McLendon R, et al. LAB-IMMUNOLOGY RESEARCH Neuro-Oncology. 14: vi38-vi42. DOI: 10.1093/Neuonc/Nos223 |
0.369 |
|
| 2011 |
Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich JN. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. Plos One. 6: e24807. PMID 21961046 DOI: 10.1371/Journal.Pone.0024807 |
0.409 |
|
| 2011 |
Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (New York, N.Y.). 333: 1453-5. PMID 21817013 DOI: 10.1126/Science.1210557 |
0.524 |
|
| 2011 |
McLendon RE, Adekunle A, Rajaram V, Koçak M, Blaney SM. Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Archives of Pathology & Laboratory Medicine. 135: 984-93. PMID 21809989 DOI: 10.5858/2010-0515-Oar1 |
0.325 |
|
| 2011 |
Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, et al. Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 118: 3003-12. PMID 21768296 DOI: 10.1182/Blood-2011-02-334565 |
0.458 |
|
| 2011 |
Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 146: 53-66. PMID 21729780 DOI: 10.1016/J.Cell.2011.06.006 |
0.388 |
|
| 2011 |
Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science (New York, N.Y.). 333: 425. PMID 21719641 DOI: 10.1126/Science.1207313 |
0.529 |
|
| 2011 |
Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117: 5351-8. PMID 21590689 DOI: 10.1002/Cncr.26188 |
0.351 |
|
| 2011 |
Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 19: 498-511. PMID 21481791 DOI: 10.1016/J.Ccr.2011.03.004 |
0.309 |
|
| 2011 |
Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 414-27. PMID 21464146 DOI: 10.6004/Jnccn.2011.0038 |
0.534 |
|
| 2011 |
Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, ... ... McLendon R, et al. The genetic landscape of the childhood cancer medulloblastoma. Science (New York, N.Y.). 331: 435-9. PMID 21163964 DOI: 10.1126/Science.1198056 |
0.617 |
|
| 2011 |
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/Neuonc/Noq157 |
0.566 |
|
| 2011 |
Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan A, Rich JN. Acidic stress promotes a glioma stem cell phenotype. Cell Death and Differentiation. 18: 829-40. PMID 21127501 DOI: 10.1038/Cdd.2010.150 |
0.349 |
|
| 2011 |
McLendon RE, Rich JN. Glioblastoma Stem Cells: A Neuropathologist's View. Journal of Oncology. 2011: 397195. PMID 21052560 DOI: 10.1155/2011/397195 |
0.403 |
|
| 2011 |
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology. 103: 371-9. PMID 20853132 DOI: 10.1007/S11060-010-0403-6 |
0.375 |
|
| 2011 |
Mattox A, Hughes B, Oleson J, Reardon D, McLendon R, Adamson C. Treatment recommendations for primary extradural meningiomas. Cancer. 117: 24-38. PMID 20824719 DOI: 10.1002/Cncr.25384 |
0.346 |
|
| 2011 |
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 101: 57-66. PMID 20443129 DOI: 10.1007/S11060-010-0217-6 |
0.524 |
|
| 2011 |
Mehta AI, Persson O, Herndon JE, Archer GE, McLendon R, Heimberger AB, Mitchell DA, Bigner DD, Sampson JH. Reply to M.S. Lesniak Journal of Clinical Oncology. 29: 3105-3106. DOI: 10.1200/Jco.2011.35.0256 |
0.374 |
|
| 2011 |
Hudson L, Kulig K, Young D, McLendon R, Abernethy A. Abstract A42: ALK and cMET expression in glioblastoma multiforme: Implications for therapeutic targeting. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A42 |
0.377 |
|
| 2010 |
Adamson DC, Rasheed BA, McLendon RE, Bigner DD. Central nervous system. Cancer Biomarkers : Section a of Disease Markers. 9: 193-210. PMID 22112477 DOI: 10.3233/Cbm-2011-0177 |
0.568 |
|
| 2010 |
Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 1: 265-77. PMID 21113414 DOI: 10.18632/Oncotarget.137 |
0.494 |
|
| 2010 |
Kuan CT, Chang J, Mansson JE, Li J, Pegram C, Fredman P, McLendon RE, Bigner DD. Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis. Bmc Developmental Biology. 10: 114. PMID 21087515 DOI: 10.1186/1471-213X-10-114 |
0.439 |
|
| 2010 |
Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/Jco.2010.28.6963 |
0.498 |
|
| 2010 |
Kuan CT, Wakiya K, Herndon JE, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. Bmc Cancer. 10: 468. PMID 20809959 DOI: 10.1186/1471-2407-10-468 |
0.519 |
|
| 2010 |
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 12: 1300-10. PMID 20716591 DOI: 10.1093/Neuonc/Noq099 |
0.365 |
|
| 2010 |
Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes & Cancer. 1: 50-61. PMID 20657792 DOI: 10.1177/1947601909356352 |
0.375 |
|
| 2010 |
Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 398: 585-7. PMID 20603105 DOI: 10.1016/J.Bbrc.2010.06.125 |
0.499 |
|
| 2010 |
Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, Lloyd RV. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocrine Pathology. 21: 161-5. PMID 20480258 DOI: 10.1007/S12022-010-9120-0 |
0.384 |
|
| 2010 |
Jin G, Cook S, Cui B, Chen WC, Keir ST, Killela P, Di C, Payne CA, Gregory SG, McLendon R, Bigner DD, Yan H. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro-Oncology. 12: 956-66. PMID 20472715 DOI: 10.1093/Neuonc/Noq045 |
0.525 |
|
| 2010 |
Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 6: 421-32. PMID 20452317 DOI: 10.1016/J.Stem.2010.02.018 |
0.352 |
|
| 2010 |
Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich JN. Targeting A20 decreases glioma stem cell survival and tumor growth. Plos Biology. 8: e1000319. PMID 20186265 DOI: 10.1371/Journal.Pbio.1000319 |
0.335 |
|
| 2010 |
Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Research. 70: 181-91. PMID 20028867 DOI: 10.1158/0008-5472.Can-09-2331 |
0.568 |
|
| 2010 |
Aliabadi H, Vredenburgh JJ, Everson RG, Desjardins A, Friedman HS, McLendon RE, Tucci DL, Sampson JH. Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. Journal of Neuro-Oncology. 98: 427-30. PMID 20020179 DOI: 10.1007/S11060-009-0091-2 |
0.369 |
|
| 2010 |
Kato Y, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, MÃ¥nsson JE, Bigner DD. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochemical and Biophysical Research Communications. 391: 750-5. PMID 19944071 DOI: 10.1016/J.Bbrc.2009.11.132 |
0.456 |
|
| 2010 |
Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. International Journal of Cancer. Journal International Du Cancer. 127: 598-611. PMID 19937796 DOI: 10.1002/Ijc.25062 |
0.485 |
|
| 2010 |
Reitman ZJ, Olby NJ, Mariani CL, Thomas R, Breen M, Bigner DD, McLendon RE, Yan H. IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer. Journal International Du Cancer. 127: 245-6. PMID 19877121 DOI: 10.1002/Ijc.25017 |
0.451 |
|
| 2010 |
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 96: 219-30. PMID 19562254 DOI: 10.1007/S11060-009-9950-0 |
0.416 |
|
| 2010 |
Gururangan S, Vredenburgh JJ, Desjardins A, Peters K, Herndon JE, McLendon RE, Janney D, Friedman HS, Reardon DA. CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma. Journal of Clinical Oncology. 28: 2089-2089. DOI: 10.1200/Jco.2010.28.15_Suppl.2089 |
0.347 |
|
| 2010 |
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Norfleet J, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. Journal of Clinical Oncology. 28: 2055-2055. DOI: 10.1200/Jco.2010.28.15_Suppl.2055 |
0.352 |
|
| 2010 |
Eyler CE, Forrester MT, MacSwords JM, Wu Q, LaFiura KM, Lathia JD, Sloan AE, Lee J, McLendon RE, Hjelmeland AB, Rich JN. Abstract 3318: Molecular targeting of brain tumor stem cells Cancer Research. 70: 3318-3318. DOI: 10.1158/1538-7445.Am10-3318 |
0.397 |
|
| 2010 |
Wortham M, Adamson DC, Shi Q, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, Yan H. Abstract 233: OTX2 copy number gain is a driver event in Shh-independent medulloblastomas Cancer Research. 70: 233-233. DOI: 10.1158/1538-7445.Am10-233 |
0.552 |
|
| 2009 |
Adamson DC, Lin N, Di C, Bortoff K, Fu J, Truszkowski P, Killela P, Duncan C, McLendon R, Bigner D. Genome Mapping of Glioblastoma Identifies a Novel Epigenetically-Silenced, Migration-Related Gene, Adherens Junctional Associated Protein, Whose Restoration of Expression by Demethylating Agents Can Inhibit Cell Migration: 972. Neurosurgery. 65: 424. PMID 28173148 DOI: 10.1227/01.Neu.0000358743.40035.E3 |
0.436 |
|
| 2009 |
Kuan CT, Wikstrand CJ, McLendon RE, Zalutsky MR, Kumar U, Bigner DD. Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. Hybridoma (2005). 28: 389-403. PMID 20025498 DOI: 10.1089/Hyb.2009.0049 |
0.446 |
|
| 2009 |
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101: 1986-94. PMID 19920819 DOI: 10.1038/Sj.Bjc.6605412 |
0.508 |
|
| 2009 |
Lu Z, Zhou L, Killela P, Rasheed AB, Di C, Poe WE, McLendon RE, Bigner DD, Nicchitta C, Yan H. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Research. 69: 9105-11. PMID 19920201 DOI: 10.1158/0008-5472.Can-09-2775 |
0.553 |
|
| 2009 |
Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications. 390: 547-51. PMID 19818334 DOI: 10.1016/J.Bbrc.2009.10.001 |
0.482 |
|
| 2009 |
Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathology (Zurich, Switzerland). 19: 713-23. PMID 19744042 DOI: 10.1111/J.1750-3639.2009.00318.X |
0.49 |
|
| 2009 |
Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, McLendon R, Wesseling P. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathology (Zurich, Switzerland). 19: 661-71. PMID 19744038 DOI: 10.1111/J.1750-3639.2009.00320.X |
0.31 |
|
| 2009 |
Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nuclear Medicine and Biology. 36: 659-69. PMID 19647172 DOI: 10.1016/J.Nucmedbio.2009.04.003 |
0.469 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology. 95: 393-400. PMID 19533023 DOI: 10.1007/S11060-009-9937-X |
0.382 |
|
| 2009 |
Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 15: 501-13. PMID 19477429 DOI: 10.1016/J.Ccr.2009.03.018 |
0.383 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-Oncology. 11: 556-61. PMID 19289491 DOI: 10.1215/15228517-2009-007 |
0.441 |
|
| 2009 |
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 360: 765-73. PMID 19228619 DOI: 10.1056/Nejmoa0808710 |
0.534 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1262-7. PMID 19204199 DOI: 10.1200/Jco.2008.18.8417 |
0.49 |
|
| 2009 |
Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1064-8. PMID 19188181 DOI: 10.1158/1078-0432.Ccr-08-2130 |
0.499 |
|
| 2009 |
Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, Febbo PG, Wechsler-Reya RJ. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 15: 135-47. PMID 19185848 DOI: 10.1016/J.Ccr.2008.12.016 |
0.343 |
|
| 2009 |
Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ, Chu CT. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathology (Zurich, Switzerland). 19: 439-48. PMID 18652591 DOI: 10.1111/J.1750-3639.2008.00196.X |
0.685 |
|
| 2009 |
Wang H, Lathia J, Wu Q, Wang J, Li Z, Heddleston J, Eyler C, Elderbroom J, McLendon R, Wang X, Hjelmland A, Rich J. Abstract C13: Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-C13 |
0.302 |
|
| 2008 |
Anders CK, Hsu DS, Acharya CR, McLendon R, Sampson JH, Vredenburgh JJ, Satterfield D, Spector N, Potti A, Blackwell KL. A genomic approach to define important and targetable molecular pathways in brain metastasis arising from solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11041. PMID 27947651 DOI: 10.1200/Jco.2008.26.15_Suppl.11041 |
0.371 |
|
| 2008 |
Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. c-Myc is required for maintenance of glioma cancer stem cells. Plos One. 3: e3769. PMID 19020659 DOI: 10.1371/Journal.Pone.0003769 |
0.333 |
|
| 2008 |
Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (Dayton, Ohio). 26: 3027-36. PMID 18802038 DOI: 10.1634/Stemcells.2007-1073 |
0.38 |
|
| 2008 |
McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, Yung WKA, Bogler O, Weinstein JN, VandenBerg S, Berger M, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature. 455: 1061-1068. PMID 18772890 DOI: 10.1038/Nature07385 |
0.308 |
|
| 2008 |
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, N.Y.). 321: 1807-12. PMID 18772396 DOI: 10.1126/Science.1164382 |
0.527 |
|
| 2008 |
Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology. 10: 745-51. PMID 18755919 DOI: 10.1215/15228517-2008-044 |
0.341 |
|
| 2008 |
Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Research. 68: 6043-8. PMID 18676824 DOI: 10.1158/0008-5472.Can-08-1079 |
0.411 |
|
| 2008 |
Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4859-68. PMID 18676759 DOI: 10.1158/1078-0432.Ccr-07-4807 |
0.467 |
|
| 2008 |
Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK, Yachnis AT, Montine TJ, Boyer PJ, Powell SZ, Prayson RA, McLendon RE. Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Archives of Pathology & Laboratory Medicine. 132: 993-1007. PMID 18517285 DOI: 10.1043/1543-2165(2008)132[993:Snuaro]2.0.Co;2 |
0.371 |
|
| 2008 |
Parisi JE, Miller DV, Boyer PJ, Brat DJ, Cochran EJ, Cohen ML, Demasters BK, Dolinak D, McComb RD, McLendon RE, Powell SZ, Prayson RA, Vinters HV, Yachnis AT. Protocol for the examination of specimens from patients with tumors of the brain/spinal cord. Archives of Pathology & Laboratory Medicine. 132: 907-12. PMID 18517271 DOI: 10.1043/1543-2165(2008)132[907:Pfteos]2.0.Co;2 |
0.326 |
|
| 2008 |
Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10: 320-9. PMID 18403491 DOI: 10.1215/15228517-2008-012 |
0.536 |
|
| 2008 |
Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro-Oncology. 10: 330-40. PMID 18359865 DOI: 10.1215/15228517-2008-003 |
0.331 |
|
| 2008 |
Davis FG, Malmer BS, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brännström T, Bruner JM, Burger PC, Collins VP, Inskip PD, Kruchko C, McCarthy BJ, McLendon RE, Sadetzki S, Tihan T, et al. Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 484-9. PMID 18349266 DOI: 10.1158/1055-9965.Epi-07-0725 |
0.541 |
|
| 2008 |
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 10: 182-9. PMID 18287339 DOI: 10.1215/15228517-2007-053 |
0.509 |
|
| 2008 |
Mott RT, Turner KC, Bigner DD, McLendon RE. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. Journal of Neurosurgery. 108: 330-5. PMID 18240930 DOI: 10.3171/Jns/2008/108/2/0330 |
0.547 |
|
| 2008 |
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 271-8. PMID 18182667 DOI: 10.1200/Jco.2007.13.3652 |
0.386 |
|
| 2008 |
Hasselblatt M, Jeibmann A, Guerry M, Senner V, Paulus W, McLendon RE. Choroid plexus papilloma with neuropil-like islands. The American Journal of Surgical Pathology. 32: 162-6. PMID 18162784 DOI: 10.1097/Pas.0B013E3180Cc2015 |
0.354 |
|
| 2008 |
Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 30-8. PMID 18077533 DOI: 10.2967/Jnumed.107.046938 |
0.559 |
|
| 2008 |
Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 10: 10-8. PMID 17951512 DOI: 10.1215/15228517-2007-035 |
0.384 |
|
| 2008 |
Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathologica. 115: 261-2. PMID 17926052 DOI: 10.1007/S00401-007-0279-5 |
0.342 |
|
| 2008 |
Mitchell D, Archer GE, Bigner DD, Friedman HS, Lally-Goss D, Herndon JE, McGehee S, McLendon R, Reardon DA, Sampson JH. Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM Journal of Clinical Oncology. 26: 2042-2042. DOI: 10.1200/Jco.2008.26.15_Suppl.2042 |
0.456 |
|
| 2007 |
McLendon RE, Turner K, Perkinson K, Rich J. Second messenger systems in human gliomas. Archives of Pathology & Laboratory Medicine. 131: 1585-90. PMID 17922598 DOI: 10.1043/1543-2165(2007)131[1585:Smsihg]2.0.Co;2 |
0.379 |
|
| 2007 |
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology. 34: 405-13. PMID 17499730 DOI: 10.1016/J.Nucmedbio.2007.01.009 |
0.531 |
|
| 2007 |
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology. 83: 53-60. PMID 17245623 DOI: 10.1007/S11060-006-9302-2 |
0.379 |
|
| 2007 |
Grunkemeier MN, Turner K, McLendon RE. Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR. Acta Neuropathologica. 113: 217-9. PMID 17151838 DOI: 10.1007/S00401-006-0175-4 |
0.429 |
|
| 2007 |
Affronti ML, Day JM, Herndon JE, Rich JN, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, McLendon RE, Friedman HS. Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients Journal of Clinical Oncology. 25: 2068-2068. DOI: 10.1200/Jco.2007.25.18_Suppl.2068 |
0.338 |
|
| 2006 |
Ochiai H, Pernell CT, Archer GE, Chewning TA, McLendon RE, Friedman HS, Sampson JH. Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurologia Medico-Chirurgica. 46: 485-9; discussion 48. PMID 17062987 DOI: 10.2176/Nmc.46.485 |
0.303 |
|
| 2006 |
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444: 756-60. PMID 17051156 DOI: 10.1038/Nature05236 |
0.476 |
|
| 2006 |
Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE, Bierau K, Bigley J, Bigner DD, Friedman HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Molecular Cancer Therapeutics. 5: 2531-9. PMID 17041097 DOI: 10.1158/1535-7163.Mct-06-0106 |
0.477 |
|
| 2006 |
Fouladi M, Blaney SM, Poussaint TY, Freeman BB, McLendon R, Fuller C, Adesina AM, Hancock ML, Danks MK, Stewart C, Boyett JM, Gajjar A. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 107: 2291-7. PMID 17019740 DOI: 10.1002/Cncr.22241 |
0.389 |
|
| 2006 |
Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Research. 66: 8722-30. PMID 16951188 DOI: 10.1158/0008-5472.Can-06-0284 |
0.54 |
|
| 2006 |
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research. 66: 7843-8. PMID 16912155 DOI: 10.1158/0008-5472.Can-06-1010 |
0.547 |
|
| 2006 |
Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 912-8. PMID 16741299 |
0.468 |
|
| 2006 |
Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 860-8. PMID 16467100 DOI: 10.1158/1078-0432.Ccr-05-2215 |
0.519 |
|
| 2006 |
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 115-22. PMID 16382120 DOI: 10.1200/Jco.2005.03.4082 |
0.551 |
|
| 2006 |
Chintagumpala MM, Friedman HS, Stewart CF, Kepner J, McLendon RE, Modrich PL, McCluggage C, Burger P, Holmes E, Thompson S, Rutka J, Michalski J, Woo S, Blaney SM, Kun LE, et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. Journal of Neuro-Oncology. 77: 193-8. PMID 16314955 DOI: 10.1007/S11060-005-9024-X |
0.488 |
|
| 2005 |
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9359-68. PMID 16361636 DOI: 10.1200/Jco.2005.03.2185 |
0.353 |
|
| 2005 |
Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8145-57. PMID 16299247 DOI: 10.1158/1078-0432.Ccr-05-0319 |
0.537 |
|
| 2005 |
Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7178-87. PMID 16192602 DOI: 10.1200/Jco.2005.06.502 |
0.472 |
|
| 2005 |
McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 104: 1693-9. PMID 16116609 DOI: 10.1002/cncr.21362 |
0.459 |
|
| 2005 |
Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1042-51. PMID 15937318 |
0.476 |
|
| 2005 |
Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK, Dobra A, Dressman HK, Bigner DD, Nevins JR, West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research. 65: 4051-8. PMID 15899794 DOI: 10.1158/0008-5472.Can-04-3936 |
0.514 |
|
| 2005 |
Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Research. 65: 919-24. PMID 15705891 |
0.406 |
|
| 2005 |
Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology. 7: 90-6. PMID 15701286 DOI: 10.1215/S1152851703000589 |
0.542 |
|
| 2005 |
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics. 4: 101-12. PMID 15657358 |
0.436 |
|
| 2005 |
Vredenburgh JJ, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Zalutsky M, Bigner D. Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors Journal of Clinical Oncology. 23: 1510-1510. DOI: 10.1200/Jco.2005.23.16_Suppl.1510 |
0.354 |
|
| 2004 |
Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Research. 64: 5048-50. PMID 15289301 DOI: 10.1158/0008-5472.Can-04-1170 |
0.502 |
|
| 2004 |
Wiltshire RN, Herndon JE, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. The Journal of Molecular Diagnostics : Jmd. 6: 166-79. PMID 15269292 DOI: 10.1016/S1525-1578(10)60507-7 |
0.504 |
|
| 2004 |
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/Jco.2004.08.110 |
0.528 |
|
| 2003 |
Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5514-20. PMID 14654531 |
0.405 |
|
| 2003 |
Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809 |
0.553 |
|
| 2003 |
Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2187-91. PMID 12775745 DOI: 10.1200/Jco.2003.10.096 |
0.361 |
|
| 2003 |
George DH, Scheithauer BW, Aker FV, Kurtin PJ, Burger PC, Cameselle-Teijeiro J, McLendon RE, Parisi JE, Paulus W, Roggendorf W, Sotelo C. Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. The American Journal of Surgical Pathology. 27: 487-93. PMID 12657933 DOI: 10.1097/00000478-200304000-00008 |
0.554 |
|
| 2003 |
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/Jco.2003.01.009 |
0.526 |
|
| 2002 |
McLendon RE, Provenzale J. Glioneuronal tumors of the central nervous system. Brain Tumor Pathology. 19: 51-8. PMID 12622133 DOI: 10.1007/Bf02478927 |
0.403 |
|
| 2002 |
Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3496-502. PMID 12429640 |
0.478 |
|
| 2002 |
Akabani G, McLendon RE, Bigner DD, Zalutsky MR. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. International Journal of Radiation Oncology, Biology, Physics. 54: 1259-75. PMID 12419456 DOI: 10.1016/S0360-3016(02)03794-X |
0.536 |
|
| 2002 |
Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 94: 2688-97. PMID 12173338 DOI: 10.1002/cncr.10544 |
0.463 |
|
| 2002 |
Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2277-83. PMID 11980998 DOI: 10.1200/Jco.2002.09.084 |
0.522 |
|
| 2002 |
Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Archives of Pathology & Laboratory Medicine. 126: 540-4. PMID 11958658 DOI: 10.1043/0003-9985(2002)126<0540:Mamoai>2.0.Co;2 |
0.563 |
|
| 2002 |
Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncology. 4: 102-8. PMID 11916501 DOI: 10.1093/neuonc/4.2.109 |
0.438 |
|
| 2002 |
Aldosari N, Wiltshire RN, Dutra A, Schrock E, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro-Oncology. 4: 75-85. PMID 11916498 DOI: 10.1093/Neuonc/4.2.75 |
0.439 |
|
| 2002 |
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1389-97. PMID 11870184 DOI: 10.1200/Jco.20.5.1389 |
0.52 |
|
| 2002 |
Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 50: 158-64; discussion 1. PMID 11844246 DOI: 10.1097/00006123-200201000-00024 |
0.52 |
|
| 2001 |
Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology. 3: 246-50. PMID 11584894 DOI: 10.1093/Neuonc/3.4.246 |
0.358 |
|
| 2001 |
Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. A genetically tractable model of human glioma formation. Cancer Research. 61: 3556-60. PMID 11325817 |
0.448 |
|
| 2001 |
Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, McLendon RE. Ham56-immunoreactive macrophages in untreated infiltrating gliomas. Archives of Pathology & Laboratory Medicine. 125: 637-41. PMID 11300934 DOI: 10.1043/0003-9985(2001)125<0637:Himiui>2.0.Co;2 |
0.591 |
|
| 2000 |
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3862-72. PMID 11078500 DOI: 10.1200/Jco.2000.18.22.3862 |
0.509 |
|
| 2000 |
Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 4148-53. PMID 11051269 |
0.411 |
|
| 2000 |
Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3522-8. PMID 11032594 DOI: 10.1200/jco.2000.18.20.3522 |
0.361 |
|
| 2000 |
McLendon RE, Wikstrand CJ, Matthews MR, Al-Baradei R, Bigner SH, Bigner DD. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 48: 1103-10. PMID 10898803 DOI: 10.1177/002215540004800807 |
0.551 |
|
| 2000 |
Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, McLendon RE. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathologica. 99: 563-70. PMID 10805102 DOI: 10.1007/S004010051161 |
0.555 |
|
| 2000 |
Aldosari N, Rasheed BK, McLendon RE, Friedman HS, Bigner DD, Bigner SH. Characterization of chromosome 17 abnormalities in medulloblastomas. Acta Neuropathologica. 99: 345-51. PMID 10787031 DOI: 10.1007/S004010051134 |
0.435 |
|
| 2000 |
Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. International Journal of Radiation Oncology, Biology, Physics. 46: 947-58. PMID 10705017 DOI: 10.1016/S0360-3016(99)00500-3 |
0.51 |
|
| 2000 |
Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. Journal of Neuroimmunology. 103: 16-25. PMID 10674985 DOI: 10.1016/S0165-5728(99)00172-1 |
0.515 |
|
| 1999 |
Bigner SH, Rasheed BK, Wiltshire R, McLendon RE. Morphologic and molecular genetic aspects of oligodendroglial neoplasms. Neuro-Oncology. 1: 52-60. PMID 11550302 DOI: 10.1093/Neuonc/1.1.52 |
0.338 |
|
| 1999 |
Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. Journal of Neuro-Oncology. 44: 233-41. PMID 10720203 DOI: 10.1023/A:1006304424346 |
0.403 |
|
| 1999 |
Chu CT, Howell DN, Morgenlander JC, Hulette CM, McLendon RE, Miller SE. Electron microscopic diagnosis of human flavivirus encephalitis: use of confocal microscopy as an aid. The American Journal of Surgical Pathology. 23: 1217-26. PMID 10524522 DOI: 10.1097/00000478-199910000-00006 |
0.65 |
|
| 1999 |
Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 2646-52. PMID 10499644 |
0.5 |
|
| 1999 |
McLendon RE, Archer GE, Larsen RH, Akabani G, Bigner DD, Zalutsky MR. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 45: 491-9. PMID 10487576 DOI: 10.1016/S0360-3016(99)00206-0 |
0.468 |
|
| 1999 |
Cummings TJ, Hulette CM, Longee DC, Bottom KS, McLendon RE, Chu CT. Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. Clinical Neuropathology. 18: 190-7. PMID 10442461 |
0.651 |
|
| 1999 |
Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. The American Journal of Pathology. 155: 375-86. PMID 10433931 DOI: 10.1016/S0002-9440(10)65134-6 |
0.524 |
|
| 1999 |
Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS. Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1183-8. PMID 10353755 DOI: 10.1097/00006123-199909000-00095 |
0.494 |
|
| 1999 |
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1516-25. PMID 10334539 DOI: 10.1200/Jco.1999.17.5.1516 |
0.509 |
|
| 1999 |
Dash RC, Provenzale JM, McComb RD, Perry DA, Longee DC, McLendon RE. Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. Archives of Pathology & Laboratory Medicine. 123: 342-5. PMID 10320149 DOI: 10.1043/0003-9985(1999)123<0342:Msggcg>2.0.Co;2 |
0.372 |
|
| 1999 |
Dodd LG, Marom EM, Dash RC, Matthews MR, McLendon RE. Fine-needle aspiration cytology of "ancient" schwannoma. Diagnostic Cytopathology. 20: 307-11. PMID 10319234 DOI: 10.1002/(Sici)1097-0339(199905)20:5<307::Aid-Dc12>3.0.Co;2-F |
0.329 |
|
| 1999 |
Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, McLendon RE, Houghton PJ, Arbuck S, Cokgor I, Friedman AH. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer. 85: 1160-5. PMID 10091802 DOI: 10.1002/(Sici)1097-0142(19990301)85:5<1160::Aid-Cncr21>3.0.Co;2-F |
0.402 |
|
| 1999 |
Cummings TJ, Chu CT, McLendon RE. LONG TERM RECURRENT JUVENILE PILOCYTIC ASTROCYTOMAS OF THE CEREBELLUM Journal of Neuropathology and Experimental Neurology. 58: 538. DOI: 10.1097/00005072-199905000-00126 |
0.503 |
|
| 1998 |
Moghrabi A, Friedman HS, Ashley DM, Bottom KS, Kerby T, Stewart E, Bruggers C, Provenzale JM, Champagne M, Hershon L, Watral M, Ryan J, Rasheed K, Lovell S, Korones D, ... ... McLendon RE, et al. Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas. Neurosurgical Focus. 4: e3. PMID 17168503 DOI: 10.3171/Foc.1998.4.4.6 |
0.334 |
|
| 1998 |
Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. Journal of Neuro-Oncology. 40: 51-7. PMID 9874186 DOI: 10.1023/A:1006082622699 |
0.339 |
|
| 1998 |
Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3851-7. PMID 9850030 DOI: 10.1200/Jco.1998.16.12.3851 |
0.533 |
|
| 1998 |
Koen JL, McLendon RE, George TM. Intradural spinal teratoma: evidence for a dysembryogenic origin. Report of four cases. Journal of Neurosurgery. 89: 844-51. PMID 9817426 DOI: 10.3171/Jns.1998.89.5.0844 |
0.307 |
|
| 1998 |
Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3570-5. PMID 9817277 DOI: 10.1200/Jco.1998.16.11.3570 |
0.513 |
|
| 1998 |
Komori T, Scheithauer BW, Anthony DC, Rosenblum MK, McLendon RE, Scott RM, Okazaki H, Kobayashi M. Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. The American Journal of Surgical Pathology. 22: 1171-83. PMID 9777979 DOI: 10.1097/00000478-199810000-00002 |
0.334 |
|
| 1998 |
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2202-12. PMID 9626222 DOI: 10.1200/Jco.1998.16.6.2202 |
0.55 |
|
| 1998 |
McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS. Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Laboratory Investigation; a Journal of Technical Methods and Pathology. 78: 643-4. PMID 9605190 |
0.307 |
|
| 1998 |
McCowage GB, Friedman HS, Moghrabi A, Kerby T, Ferrell L, Stewart E, Duncan-Brown M, Fuchs HE, Tien R, McLendon RE, Meier L, Kurtzberg J, Ashley D, Colvin OM, Longee DC. Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. Medical and Pediatric Oncology. 30: 75-80. PMID 9403013 DOI: 10.1002/(Sici)1096-911X(199802)30:2<75::Aid-Mpo1>3.0.Co;2-X |
0.385 |
|
| 1998 |
Chu CT, Howell DN, Morgenlander JC, McLendon RE, Miller SE. ELECTRON MICROSCOPIC DIAGNOSIS OF ARBOVIRAL MENINOOENCEPHALITIS Journal of Neuropathology and Experimental Neurology. 57: 505. DOI: 10.1097/00005072-199805000-00161 |
0.485 |
|
| 1998 |
s M, Rasheed B, McLendon RE, Wikstrand CJ, Bigner DD, Bigner SH. MOLECULAR AND IMMUNOHISTOLOGIC (IHC) STUDIES ON OLIGODENDROGLIAL (O) TUMORS Journal of Neuropathology and Experimental Neurology. 57: 473. DOI: 10.1097/00005072-199805000-00029 |
0.492 |
|
| 1997 |
Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Research. 57: 4187-90. PMID 9331072 |
0.45 |
|
| 1997 |
Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Research. 57: 4130-40. PMID 9307304 |
0.446 |
|
| 1997 |
Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS. Chromosomal characteristics of childhood brain tumors. Cancer Genetics and Cytogenetics. 97: 125-34. PMID 9283596 DOI: 10.1016/S0165-4608(96)00404-9 |
0.369 |
|
| 1997 |
Provenzale JM, Schaefer P, Traweek ST, Ferry J, Moore JO, Friedman AH, McLendon RE. Craniocerebral plasmacytoma: MR features. Ajnr. American Journal of Neuroradiology. 18: 389-92. PMID 9111682 DOI: 10.1097/00041327-199906000-00023 |
0.339 |
|
| 1997 |
Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 39: 307-16. PMID 9025771 DOI: 10.1007/S002800050577 |
0.491 |
|
| 1997 |
Ashraf R, Bentley RC, Awan AN, McLendon RE, Ragozzino MW. Implantation metastasis of primary malignant rhabdoid tumor of the brain in an adult (one case report). Medical and Pediatric Oncology. 28: 223-7. PMID 9024522 DOI: 10.1002/(Sici)1096-911X(199703)28:3<223::Aid-Mpo14>3.0.Co;2-F |
0.338 |
|
| 1997 |
Moghrabi A, Tien R, Fuchs H, Longee D, McLendon R, Friedman HS. False positive images in the follow-up of patients with brain tumors. Medical and Pediatric Oncology. 28: 127-31. PMID 8986148 DOI: 10.1002/(Sici)1096-911X(199702)28:2<127::Aid-Mpo6>3.0.Co;2-M |
0.387 |
|
| 1997 |
Matthews M, Friedman A, Wikstrand C, Bigner D, McLendon R. EXTRACELLULAR MATRIX ANTIGENS IN CAPILLARY HEMANGIOBLASTOMA Journal of Neuropathology and Experimental Neurology. 56: 612. DOI: 10.1097/00005072-199705000-00179 |
0.385 |
|
| 1997 |
Bean J, Archer G, Munley M, Ong E, Snyder S, Haroon Z, McLendon R, Marks L, Stratford M, Chaplin D, Brizel D, Bigner D, Dewhirst M. 2013 The impact of hypoxia and oxygenation modification on the radiation response of an intracranial rat glioma International Journal of Radiation Oncology*Biology*Physics. 39: 247. DOI: 10.1016/S0360-3016(97)80782-1 |
0.412 |
|
| 1996 |
Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 2: 963-72. PMID 9816257 |
0.448 |
|
| 1996 |
Blaeker H, Rasheed BK, McLendon RE, Friedman HS, Batra SK, Fuchs HE, Bigner SH. Microsatellite analysis of childhood brain tumors. Genes, Chromosomes & Cancer. 15: 54-63. PMID 8824726 DOI: 10.1002/(Sici)1098-2264(199601)15:1<54::Aid-Gcc8>3.0.Co;2-3 |
0.351 |
|
| 1996 |
McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. International Journal of Radiation Oncology, Biology, Physics. 35: 69-80. PMID 8641929 DOI: 10.1016/S0360-3016(96)85013-9 |
0.443 |
|
| 1996 |
McLendon RE, Fung KM, Bentley RC, Ahmed Rasheed BK, Trojanowski JQ, Bigner SH, Bigner DD, Friedman HS. Production and characterization of two ependymoma xenografts. Journal of Neuropathology and Experimental Neurology. 55: 540-8. PMID 8627345 DOI: 10.1097/00005072-199605000-00007 |
0.484 |
|
| 1996 |
McCowage G, Tien R, McLendon R, Felsberg G, Fuchs H, Graham ML, Kurtzberg J, Moghrabi A, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Robertson PL, Colvin OM, Golembe B, et al. Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Medical and Pediatric Oncology. 27: 32-9. PMID 8614389 DOI: 10.1002/(Sici)1096-911X(199607)27:1<32::Aid-Mpo7>3.0.Co;2-V |
0.524 |
|
| 1996 |
Ashley DM, Longee D, Tien R, Fuchs H, Graham ML, Kurtzberg J, Casey J, Olson J, Meier L, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Colvin OM, Pipas JM, ... ... McLendon R, et al. Treatment of patients with pineoblastoma with high dose cyclophosphamide. Medical and Pediatric Oncology. 26: 387-92. PMID 8614374 DOI: 10.1002/(Sici)1096-911X(199606)26:6<387::Aid-Mpo3>3.0.Co;2-D |
0.521 |
|
| 1995 |
Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, Herndon JE, Pastan IH. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1545-55. PMID 9815955 |
0.428 |
|
| 1995 |
Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia. 15: 244-56. PMID 8586461 DOI: 10.1002/Glia.440150306 |
0.534 |
|
| 1995 |
Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH. Prognostic implications of chromosome 17p deletions in human medulloblastomas. Journal of Neuro-Oncology. 24: 39-45. PMID 8523074 DOI: 10.1007/Bf01052657 |
0.534 |
|
| 1995 |
Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. Journal of Neuro-Oncology. 24: 109-22. PMID 8523067 DOI: 10.1007/Bf01052668 |
0.544 |
|
| 1995 |
Provenzale JM, Weber AL, Klintworth GK, McLendon RE. Radiologic-pathologic correlation. Bilateral retinoblastoma with coexistent pinealoblastoma (trilateral retinoblastoma). Ajnr. American Journal of Neuroradiology. 16: 157-65. PMID 7900586 |
0.438 |
|
| 1995 |
Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, Dewhirst MW. A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery. 36: 976-84; discussion 9. PMID 7791991 DOI: 10.1227/00006123-199505000-00014 |
0.541 |
|
| 1995 |
Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon J, Bigner DD. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proceedings of the National Academy of Sciences of the United States of America. 92: 2765-9. PMID 7708720 DOI: 10.1073/Pnas.92.7.2765 |
0.497 |
|
| 1995 |
Kurpad SN, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD. Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Research. 55: 3803-9. PMID 7641197 |
0.374 |
|
| 1994 |
Moghrabi A, Friedman HS, McLendon R, Hockenberger B, Tien RD, Halperin EC, Oakes WJ. Arteriovenous malformation mimicking recurrent medulloblastoma. Medical and Pediatric Oncology. 22: 140-3. PMID 8259101 DOI: 10.1002/Mpo.2950220216 |
0.372 |
|
| 1994 |
Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH. Alterations of the TP53 gene in human gliomas. Cancer Research. 54: 1324-30. PMID 8118823 |
0.319 |
|
| 1994 |
McLendon RE, Bigner DD. Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathology (Zurich, Switzerland). 4: 221-8. PMID 7952263 DOI: 10.1111/J.1750-3639.1994.Tb00837.X |
0.443 |
|
| 1993 |
Furie DM, Felsberg GJ, Tien RD, Friedman HS, Fuchs H, McLendon R. MRI of gangliocytoma of cerebellum and spinal cord. Journal of Computer Assisted Tomography. 17: 488-91. PMID 8491919 DOI: 10.1097/00004728-199305000-00031 |
0.308 |
|
| 1993 |
McLENDON RE, BATRA SK, FRIEDMAN HS, RASHEED B, BIGNER DD, BIGNER SH. EXPRESSION OF C-MYC IN MEDULLOBLASTOMA XENOGRAFTS Journal of Neuropathology and Experimental Neurology. 52: 267. DOI: 10.1097/00005072-199305000-00030 |
0.414 |
|
| 1990 |
Szpak C, McLendon RE, Simpson JF, Thor A, Johnston WW. The application of monoclonal antibodies in the cytologic evaluation of tumors. Clinics in Laboratory Medicine. 10: 77-103. PMID 2184981 DOI: 10.1016/S0272-2712(18)30583-3 |
0.392 |
|
| 1988 |
McLendon RE, Oakes WJ, Heinz ER, Yeates AE, Burger PC. Adipose tissue in the filum terminale: a computed tomographic finding that may indicate tethering of the spinal cord. Neurosurgery. 22: 873-6. PMID 2967925 DOI: 10.1227/00006123-198805000-00010 |
0.436 |
|
| 1987 |
Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach JP, Coakham HB, de Tribolet N, Bullard DE, Zalutsky MR, Bigner DD. Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. Journal of Neuroimmunology. 15: 37-56. PMID 3571486 DOI: 10.1016/0165-5728(87)90005-1 |
0.506 |
|
| 1987 |
Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC, Bullard DE. Clinicopathologic correlations in the oligodendroglioma. Cancer. 59: 1345-52. PMID 3545437 DOI: 10.1002/1097-0142(19870401)59:7<1345::AID-CNCR2820590719>3.0.CO;2-A |
0.376 |
|
| 1987 |
McLendon RE, Burger PC, Bigner SH, Bigner DD. PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASMS IN FISCHER-344 RATS RECEIVING CHRONIC LIFETIME EXPOSURE TO ACRYLONITRILE (ACN) Journal of Neuropathology and Experimental Neurology. 46: 389. DOI: 10.1097/00005072-198705000-00178 |
0.529 |
|
| 1986 |
Woodruff WW, Yeates AE, McLendon RE. Perineural tumor extension to the cavernous sinus from superficial facial carcinoma: CT manifestations. Radiology. 161: 395-9. PMID 3763908 DOI: 10.1148/Radiology.161.2.3763908 |
0.338 |
|
| 1986 |
McLendon RE, Burger PC, Pegram CN, Eng LF, Bigner DD. The immunohistochemical application of three anti-GFAP monoclonal antibodies to formalin-fixed, paraffin-embedded, normal and neoplastic brain tissues. Journal of Neuropathology and Experimental Neurology. 45: 692-703. PMID 3534145 DOI: 10.1097/00005072-198611000-00007 |
0.566 |
|
| 1985 |
McLendon RE, Crain BJ, Oakes WJ, Burger PC. Cerebral polygyria in the Chiari Type II (Arnold-Chiari) malformation. Clinical Neuropathology. 4: 200-5. PMID 4064385 |
0.367 |
|
| 1985 |
McLendon RE, Robinson JS, Chambers DB, Grufferman S, Burger PC. The glioblastoma multiforme in Georgia, 1977-1981. Cancer. 56: 894-7. PMID 2990658 DOI: 10.1002/1097-0142(19850815)56:4<894::AID-CNCR2820560432>3.0.CO;2 |
0.48 |
|
| 1985 |
McLendon RE, Burger PC, Eng LF, Wikstrand CJ, Pegram CN, Bigner DD. PRODUCTION AND CHARACTERIZATION OF 3 MONOCLONAL ANTIBODIES (MAs) TO GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) Journal of Neuropathology and Experimental Neurology. 44: 331. DOI: 10.1097/00005072-198505000-00083 |
0.527 |
|
| Show low-probability matches. |
